Genetic regulation, physiology, assessment and inhibition of efflux pumps responsible for multi-drug resistant phenotypes of bacterial pathogens

Antibiotic Resistance: Causes and Risk Factors, Mechanisms and Alternatives

Volumn , Issue , 2011, Pages 313-332

  Amaral, Leonard ^a,b,c   Fanning, S ^c,d   Spengler, G ^a,b   Rodrigues, L ^a,b   Iversen, C ^d   Martins, M ^a,b   Martins, A ^a,b   Viveiros, M ^a,c   Couto, I ^a,e  

^a UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^b INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^c European Science Foundation   (France)

^d UNIVERSITY COLLEGE DUBLIN   (Ireland)

^e UNIVERSIDADE NOVA DE LISBOA   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79959755838     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (74)

1. Martins M., Dastidar S.G., Fanning S., Kristiansen J.E., Molnar J., Pagés J.M., Schelz Z., Spengler G., Viveiros M., Amaral L. (2008) Potential role of non-antibiotics (helper compounds) in the treatment of multidrug-resistant Gram-negative infections: mechanisms for their direct and indirect activities. Int. J. Antimicrob. Agents 31: 198-208.
2. Poole K. (2007) Efflux pumps as antimicrobial resistance mechanisms. Ann. Med. 39: 162-176.
3. Mahamoud A., Chevalier J., Davin-Regli A., Barbe J., Pagés J.M. (2006) Quinoline derivatives as promising inhibitors of antibiotic efflux pump in multidrug resistant Enterobacter aerogenes isolates. Curr. Drug Targets 7: 843-847.
4. Piddock L.J. (2006). Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin. Microbiol. Rev. 19: 382-402.
5. Pagés JM, Masi M, Barbe J. (2005) Inhibitors of efflux pumps in Gram-negative bacteria. Trends Mol. Med. 11: 382-389.
6. Martins A., Couto I., Aagaard L., Martins M., Viveiros M., Kristiansen J.E., Amaral L. (2007) Prolonged exposure of methicillin-resistant Staphylococcus aureus (MRSA) COL strain to increasing concentrations of oxacillin results in a multidrug-resistant phenotype. Int. J. Antimicrob. Agents 29: 302-305.
7. Viveiros M., Dupont M., Rodrigues L., Couto I., Davin-Regli A., Martins M., Pagés J.M., Amaral L. (2007) Antibiotic stress, genetic response and altered permeability of E. coli. PLoS ONE 2: e365.
8. Viveiros M., Jesus A., Brito M., Leandro C., Martins M., Ordway D., Molnar A.M., Molnar J., Amaral L. (2005) Inducement and reversal of tetracycline resistance in Escherichia coli K-12 and expression of proton gradient-dependent multidrug efflux pump genes. Antimicrob. Agents Chemother. 49: 3578-3582.
9. Viveiros M., Portugal I., Bettencourt R., Victor T.C., Jordaan A.M., Leandro C., Ordway D., Amaral L. (2002) Isoniazid-induced transient high-level resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 46: 2804-2810.
10. Couto I., Costa S.S., Viveiros M., Martins M., Amaral L. (2008) Efflux-mediated response of Staphylococcus aureus exposed to ethidium bromide. J. Antimicrob. Chemother. 62: 504-513.
11. Kristiansen M.M., Leandro C., Ordway D., Martins M. Viveiros M., Pacheco T., Kristiansen J.E. and Amaral L. (2005) Thioridazine Reduces Resistance Of Methicillin Resistant Staphylococcus aureus By Inhibiting A Reserpine Sensitive Efflux Pump. In Vivo 20: 361-366.
12. Kaatz G.W., Moudgal V.V., Seo S.M., Kristiansen J.E. (2003) Phenothiazines and thioxanthenes inhibit multidrug efflux pump activity in Staphylococcus aureus. Antimicrob. Agents Chemother. 47: 719-726.
13. Lomovskaya O., Bostian K.A. (2006) Practical applications and feasibility of efflux pump inhibitors in the clinic-a vision for applied use. Biochem. Pharmacol. 71:910-918.
14. Lomovskaya O., Watkins W.J. (2001) Efflux pumps: their role in antibacterial drug discovery. Curr. Med. Chem. 8:1699-1711.
15. Kamicker B.J., Sweeney M.T., Kaczmarek F., Dib-Hajj F., Shang W., Crimin K., Duignan J., Gootz T.D. (2008) Bacterial efflux pump inhibitors. Methods Mol. Med. 142: 187-204.
16. German N., Kaatz G.W., Kerns R.J. (2008) Synthesis and evaluation of PSSRI-based inhibitors of Staphylococcus aureus multidrug efflux pumps. Bioorg. Med. Chem. Lett. 18: 1368-1373.
17. Robertson G.T., Doyle T.B., Du Q., Duncan L., Mdluli K.E., Lynch A.S. (2007) A Novel indole compound that inhibits Pseudomonas aeruginosa growth by targeting MreB is a substrate for MexAB-OprM. J. Bacteriol. 189: 6870-6881.
18. Ball A.R., Casadei G., Samosorn S., Bremner J.B., Ausubel F.M., Moy T.I., Lewis K. (2006) Conjugating berberine to a multidrug efflux pump inhibitor creates an effective antimicrobial. A.C.S Chem. Biol. 1:594-600.
19. Pannek S., Higgins P.G., Steinke P., Jonas D., Akova M., Bohnert J.A., Seifert H., Kern W.V. (2006) Multidrug efflux inhibition in Acinetobacter baumannii: comparison between 1-(1-naphthylmethyl)-piperazine and phenyl-arginine-beta-naphthylamide. J. Antimicrob. Chemother. 57:970-974.
20. Ramón-García S., Martín C., Aínsa J.A., De Rossi E. (2006) Characterization of tetracycline resistance mediated by the efflux pump Tap from Mycobacterium fortuitum. J. Antimicrob. Chemother. 57:252-259.
21. Marquez B. (2005) Bacterial efflux systems and efflux pumps inhibitors. Biochimie 87: 1137-1147.
22. Hendricks O., Butterworth T.S., Kristiansen J.E. (2003) The in-vitro antimicrobial effect of non-antibiotics and putative inhibitors of efflux pumps on Pseudomonas aeruginosa and Staphylococcus aureus. Int. J. Antimicrob. Agents 22: 262-264.
23. Molnár J., Hevér A., Fakla I., Fischer J., Ocsovski I., Aszalós A. (1997) Inhibition of the transport function of membrane proteins by some substituted phenothiazines in E. coli and multidrug resistant tumor cells. Anticancer Res. 17: 481-486.
24. Amaral L., Viveiros M., Kristiansen J.E. (2006) "Non-Antibiotics": alternative therapy for the management of MDRTB and MRSA in economically disadvantaged countries. Curr. Drug Targets 7: 887-891.
25. Amaral L., Viveiros M., Molnar J. (2004) Antimicrobial activity of phenothiazines. In Vivo 18: 725-731.
26. Amaral L., Viveiros M., Kristiansen J.E. (2001) Phenothiazines: potential alternatives for the management of antibiotic resistant infections of tuberculosis and malaria in developing countries. Trop. Med. Int. Health 6: 1016-1022.
27. Amaral L., Kristiansen J.E., Viveiros M., Atouguia J. (2001) Activity of phenothiazines against antibiotic-resistant Mycobacterium tuberculosis: a review supporting further studies that may elucidate the potential use of thioridazine as anti-tuberculosis therapy. J. Antimicrob. Chemother. 47: 505-511.
28. Amaral L., Kristiansen J.E. (2000) Phenothiazines: an alternative to conventional therapy for the initial management of suspected multidrug resistant tuberculosis. A call for studies. Int. J. Antimicrob. Agents 14: 173-176.
29. Lorca G.L., Barabote R.D., Zlotopolski V., Tran C., Winnen B., Hvorup R.N., Stonestrom A.J., Nguyen E., Huang L.W., Kim D.S., Saier M.H. Jr. (2007) Transport capabilities of eleven gram-positive bacteria: comparative genomic analyses. Biochim. Biophys. Acta 1768: 1342-1366.
30. Piddock L.J., Jin Y.F. (1999) Antimicrobial activity and accumulation of moxifloxacin in quinolone-susceptible bacteria. J. Antimicrob. Chemother. 43: 39-42.
31. Munoz-Bellido J.L., Alonzo Manzanares M., Martinez Andrés J.A., Guttiérrez Zufiaurre M.N., Ortiz G., Segovia Hernández M., Garcia-Rodriguez JA. (1999) Efflux pump-mediated quinolone resistance in Staphylococcus aureus strains wild type for gyrA, gyrB, grlA, and norA. Antimicrob. Agents Chemother. 43: 354-356.
32. Jia B., Zhou T.Q., Huang A.L., Huang W.X. (2008) Role of TMS5: staphylococcal multidrug-efflux protein QacA. Chin. Med. J. (Engl). 121: 409-413.
33. Smith K., Gemmell C.G., Hunter I.S. (2008) The association between biocide tolerance and the presence or absence of qac genes among hospital-acquired and community-acquired MRSA isolates. J. Antimicrob. Chemother. 61: 78-84.
34. Sekiguchi J., Hama T., Fujino T., Araake M., Irie A., Saruta K., Konosaki H., Nishimura H., Kawano A., Kudo K., Kondo T., Sasazuki T., Kuratsuji T., Yoshikura H., Kirikae T. (2004) Detection of the antiseptic-and disinfectant-resistance genes qacA, qacB, and qacC in methicillin-resistant Staphylococcus aureus isolated in a Tokyo hospital. Jpn. J. Infect. Dis. 57: 288-291.
35. Piddock L.J., Johnson M.M., Simjee S., Pumbwe L. (2002) Expression of efflux pump gene pmrA in fluoroquinolone-resistant and-susceptible clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 46: 808-812.
36. German N, Wei P, Kaatz GW, Kerns RJ. (2008) Synthesis and evaluation of fluoroquinolone derivatives as substrate-based inhibitors of bacterial efflux pumps. Eur. J. Med. Chem. 43: 2453-2463.
37. Thota N., Koul S., Reddy M.V., Sangwan P.L., Khan I.A., Kumar A., Raja A.F., Andotra S.S., Qazi G.N. (2008) Citral derived amides as potent bacterial NorA efflux pump inhibitors. Bioorg. Med. Chem. 16: 6535-6543.
38. Vidaillac C., Guillon J., Moreau S., Arpin C., Lagarděre A., Larrouture S., Dallemagne P., Caignard D.H., Quentin C., Jarry C. (2007) Synthesis of new 4-[2-(alkylamino) ethylthio]pyrrolo[1, 2-a]quinoxaline and 5-[2-(alkylamino) ethylthio]pyrrolo[1, 2-a]thieno[3, 2-e]pyrazine derivatives, as potential bacterial multidrug resistance pump inhibitors. J. Enzyme. Inhib. Med. Chem. 22: 620-631.
39. Michalet S., Cartier G., David B., Mariotte A.M., Dijoux-franca M.G., Kaatz G.W., Stavri M., Gibbons S. (2007) N-caffeoylphenalkylamide derivatives as bacterial efflux pump inhibitors. Bioorg. Med. Chem. Lett. 17: 1755-1758.
40. Vidaillac C., Guillon J., Arpin C., Forfar-Bares I., Ba B.B., Grellet J., Moreau S., Caignard D.H., Jarry C., Quentin C. (2007) Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus. Antimicrob. Agents Chemother. 51: 831-838.
41. Kaatz G.W., Seo S.M., Barriere S.L., Albrecht L.M., Rybak M.J. (1991) Development of resistance to fleroxacin during therapy of experimental methicillin-susceptible Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 35: 1547-1550.
42. Noguchi N., Okihara T., Namiki Y., Kumaki Y., Yamanaka Y., Koyama M., Wakasugi K., Sasatsu M. (2005) Susceptibility and resistance genes to fluoroquinolones in methicillin-resistant Staphylococcus aureus isolated in 2002. Int. J. Antimicrob. Agents 25: 374-379.
43. Schmitz F.J., Fluit A.C., Brisse S., Verhoef J., Köhrer K., Milatovic D. (1999) Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates. FEMS Immunol. Med. Microbiol. 26: 281-287.
44. Ng E.Y., Trucksis M., Hooper D.C. (1994) Quinolone resistance mediated by norA: physiologic characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome. Antimicrob. Agents Chemother. 38: 1345-1355.
45. Kaatz G.W., Seo S.M. (1997) Mechanisms of fluoroquinolone resistance in genetically related strains of Staphylococcus aureus. Antimicrob. Agents Chemother. 41: 2733-2737.
46. Munoz Bellido J.L., Alonso Manzanares M.A., Yagüe Guirao G., Gutiérrez Zufiaurre M.N., Toldos M.C., Segovia Hernández M., Garcia-Rodriguez J.A. (1999) In vitro activities of 13 fluoroquinolones against Staphylococcus aureus isolates with characterized mutations in gyrA, gyrB, grlA, and norA and against wild-type isolates. Antimicrob. Agents Chemother. 43: 966-968.
47. Kaatz G.W., Seo S.M. (1995) Inducible NorA-mediated multidrug resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 39: 2650-2655.
48. Lee E.W., Chen J., Huda M.N., Kuroda T., Mizushima T., Tsuchiya T. (2003) Functional cloning and expression of emeA, and characterization of EmeA, a multidrug efflux pump from Enterococcus faecalis. Biol. Pharm. Bull. 26: 266-270.
49. Spengler G., Martins A., Schelz Z., Rodrigues L., Aagaard L., Martins M., Costa S.S., Couto I., Viveiros M., Kristiansen J.E., Fanning S., Molnar J. and Amaral L. Characterisation of intrinsic efflux activity of Enterococcus faecalis ATCC29212 by a semi-automated ethidium bromide method. Accepted by In Vivo.
50. Viveiros M., Martins A., Paixao L., Rodrigues L., Martins M., Couto I., Fähnrich E., Kern W.V., Amaral L. (2008) Demonstration of intrinsic efflux activity of Escherichia coli K-12 AG100 by an automated ethidium bromide method. Int. J. Antimicrob. Agents 31: 458-462.
51. Lee E.W., Huda M.N., Kuroda T., Mizushima T., Tsuchiya T. (2003) EfrAB, an ABC multidrug efflux pump in Enterococcus faecalis. Antimicrob. Agents Chemother. 47: 3733-3738.
52. Davidson A.L., Dassa E., Orelle C., Chen J. (2008) Structure, function, and evolution of bacterial ATP-binding cassette systems. Microbiol. Mol. Biol. Rev. 72: 317-364.
53. Zakharov S.D., Li X., Red'ko T.P., Dilley R.A. (1996) Calcium binding to the subunit c of E. coli ATP-synthase and possible functional implications in energy coupling. J. Bioenerg. Biomembr. 28: 483-494.
54. Thanassi D.G. and Hultgren S.J. (2000) Multiple pathways allow protein secretion across the bacterial outer membrane. Curr. Opin. Cell Biol. 12: 420-430.
55. Borges-Walmsley M.I., McKeegan K.S., Walmsley A.R. (2003) Structure and function of efflux pumps that confer resistance to drugs. Biochem. J. 376: 313-338.
56. Delepelaire P. (2004) Type I secretion in gram-negative bacteria. Biochim. Biophys. Acta; 1694: 149-161.
57. Murakami S., Nakashima R., Yamashita E., Matsumoto T. and Yamaguchi A. (2006) Crystal structures of a multidrug transporter reveal a functionally rotating mechanism. Nature 443: 173-179.
58. Akama H., Matsuura T., Kashiwagi S., Yoneyama H., Narita S., Tsukihara T., Nakagawa A. and Nakae T. (2004) Crystal structure of the membrane fusion protein, MexA, of the multidrug transporter in Pseudomonas aeruginosa. J. Biol. Chem. 279: 25939-25942.
59. Higgins M.K., Bokma E., Koronakis E., Hughes C., Koronakis V. (2004) Structure of the periplasmic component of a bacterial drug efflux pump. Proc. Natl. Acad. Sci. U.S.A. 101: 9994-9999.
60. Fernandez-Recio J., Walas F., Federici L., Venkatesh Pratap J., Bavro V.N., Miguel R.N., Mizuguchi K. and Luisi B. (2004) A model of a transmembrane drug-efflux pump from Gram-negative bacteria. FEBSLett. 578: 5-9.
61. Lobedanz S., Bokma E., Symmons M.F., Koronakis E., Hughes C. and Koronakis V. (2007) A periplasmic coiled-coil interface underlying TolC recruitment and the assembly of bacterial drug efflux pumps. Proc. Natl. Acad. Sci. U.S.A. 104: 4612-4617.
62. Pietras Z., Bavro V.N., Furnham N., Pellegrini-Calace M., Milner-White E.J. and Luisi B.F. (2008) Structure and mechanism of drug efflux machinery in Gram negative bacteria. Curr. Drug Targets 9: 719-728.
63. Chopra I., O'Neill A.J., Miller K. (2003) The role of mutators in the emergence of antibiotic-resistant bacteria. Drug Resist. Updat. 6: 137-145.
64. Viveiros M., Martins M., Martins A., Rodrigues L., Couto I., Fanning S. and Amaral L. (2008) New methods for the identification of efflux mediated MDR bacteria, genetic assessment of regulators and efflux pump constituents, characterization of efflux systems and screening for inhibitors of efflux pumps. Curr. Drug Targets 9: 760-778.
65. Martins M., Santos B., Couto I., Viveiros M., Pages J.M., Molnar M., Cruz A. and Amaral L. (2006) Instrument free method for the demonstration and assessment of efflux pumps that cause bacterial resistance. In Vivo 20: 657-664.
66. Mahamoud A., Chevalier J., Alibert-Franco S., Kern W.V., Pagés J.M. (2007) Antibiotic efflux pumps in Gram-negative bacteria: the inhibitor response strategy. J. Antimicrob. Chemother. 59: 1223-1229.
67. Nikaido E., Yamaguchi A., Nishino K. (2008) AcrAB multidrug efflux pump regulation in Salmonella enterica serovar Typhimurium by RamA in response to environmental signals. J. Biol. Chem. 283: 24245-24253.
68. Dowd S.E., Killinger-Mann K., Brashears M., Fralick J. (2008) Evaluation of gene expression in a single antibiotic exposure-derived isolate of Salmonella enterica typhimurium 14028 possessing resistance to multiple antibiotics. Foodborne Pathog. Dis. 5: 205-221.
69. Perez J.C., Groisman E.A. (2007) Acid pH activation of the PmrA/PmrB two-component regulatory system of Salmonella enterica. Mol. Microbiol. 63: 283-293.
70. Murata T., Tseng W., Guina T., Miller S.I., Nikaido H. (2007) PhoPQ-mediated regulation produces a more robust permeability barrier in the outer membrane of Salmonella entericas serovar typhimurium. J. Bacteriol. 189: 7213-7222.
71. Gunn J.S. (2008) The Salmonella PmrAB regulon: lipopolysaccharide modifications, antimicrobial peptide resistance and more. Trends Microbiol. 16: 284-290.
72. see: http://www.rpi.edu/dept/bcbp/molbiochem/MBWeb/mb1/part2/f1fo.htm for complete review of scheme.
73. Teh J.S., Yano T., Rubin H. (2007) Type II NADH: menaquinone oxidoreductase of Mycobacterium tuberculosis. Infect. Disord. Drug Targets 7: 169-181.
74. Tran S.L., Cook G.M. (2005) The F1Fo-ATP synthase of Mycobacterium smegmatis is essential for growth. J. Bacteriol. 187: 5023-5028.